Search our Database of Scientific Publications and Authors

I’m looking for a
    Redefining Hormonal Therapy for Advanced Prostate Cancer: Results from the LATITUDE and STAMPEDE Studies.
    Cancer Cell 2017 07;32(1):6-8
    University of California, San Francisco, CA, USA. Electronic address:
    Two papers published recently in the New England Journal of Medicine describe the utility of abiraterone acetate, an androgen biosynthesis inhibitor, in the early treatment of metastatic prostate cancer. In addition to establishing a new standard of care, these two articles pose a number of important questions for future investigation.

    Similar Publications

    [Prostate cancer and new hormonal treatments: mechanism of action and main clinical results].
    Prog Urol 2013 Oct;23 Suppl 1:S34-43
    Service d'urologie, hôpital Foch, université de Versailles - Saint-Quentin-en-Yvelines (UVSQ), 92150 Suresnes, France. Electronic address:
    Introduction: New drugs have recently been developed, through a better understanding of the mechanisms involved in the progression of prostate cancer, including castration-resistant ones (CRPC). This article aims to describe the mechanisms of action of these new hormonal treatments and their major clinical outcomes and development programs.

    Materials And Methods: A bibliographic research in French and English using Medline(®) and Embase(®) using the keywords "castration-resistant prostate cancer", "abiraterone acetate", "orteronel", "enzalutamide", and "clinical trials" was performed. Read More
    Abiraterone acetate: oral androgen biosynthesis inhibitor for treatment of castration-resistant prostate cancer.
    Drug Des Devel Ther 2012 16;6:13-8. Epub 2012 Jan 16.
    Division of Hospital Medicine, UMass Memorial Healthcare, Worcester, MA 01605, USA.
    Prostate cancer is the second leading cause of cancer death in men in the US and Europe. The treatment of advanced-stage prostate cancer has been androgen deprivation. Medical castration leads to decreased production of testosterone and dihydrotestosterone by the testes, but adrenal glands and even prostate cancer tissue continue to produce androgens, which eventually leads to continued prostate cancer growth despite castrate level of androgens. Read More
    [Abiraterone acetate (AA): current guidelines of prescription of abiraterone].
    Bull Cancer 2014 Apr;101(4):388-93
    Institut Gustave-Roussy, DITEP, Département d'innovations thérapeutiques et essais précoces, 114, rue Édouard-Vaillant, 94805 Villejuif cedex, France.
    Abiraterone acetate (AA) is a selective inhibitor of cytochrom p450 (CYP)17 which is required for androgen biosynthesis, and can block the androgens synthesis by testicles, surrenals and intratumoral secretion. In phase I and II studies in patients with prostate cancer, therapy with AA 250-2000  mg once daily demonstrated reductions in prostate specific antigen (PSA), and/or circulating tumor cells (CTCs). In two large phase III trials in patients with metastatic castration resistant prostate cancer (CRPC) in post-docetaxel and pre-docetaxel setting, AA plus prednisone compared with placebo plus prednisone demonstrated a significant superior overall survival in post-docetaxel setting, and a superior radiological PFS in pre-docetaxel setting. Read More
    Pre-chemotherapy abiraterone acetate. A proposal of a treatment algorithm in castration resistant prostate cancer.
    Actas Urol Esp 2014 Jun 15;38(5):327-33. Epub 2013 Dec 15.
    UGC de Urología, Hospital Universitario San Cecilio, Instituto de Investigación Biosanitaria de Granada, Granada, España.
    Context: Prostate cancer treatment remains a challenge for the urologist. Medical control in locally advanced or metastatic prostate cancer is usually performed with LHRH analogues and/or antiandrogens. Different treatments have been proposed when there is biochemical and clinical progression of the disease and other new ones have changed the patients' perspective and life expectancy. Read More